(Press-News.org) TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B. Helmsley Charitable Trust, a new research grant aimed at developing a novel treatment for type 1 diabetes (T1D). This award is made through TRxA’s Bridging Research and Innovation in Drug Development Grants (BRIDGe) program, which is designed to support academic researchers in traversing the drug development valley of death and advancing new cutting-edge therapeutics from the lab to patients.
Feroz Papa, M.D., Ph.D. and Bradley Backes, Ph.D., both from the University of California, San Francisco, in collaboration with Dustin Maly, Ph.D., from the University of Washington, Seattle, have received this TRxA award to develop kinase inhibitors that target critical pathways in the onset of T1D. “More than 1.3 million Americans currently live with T1D, with first degree relatives of patients being at risk for developing the condition,” explained Papa. “This grant will enable our research team to further develop our novel drug candidate to prevent and even reverse T1D.”
The Helmsley Charitable Trust is partnering with TRxA to support this project, with a matching investment of $500,000, bringing the total grant award to $1 million. “Existing therapies for T1D fall short of easing the burdens of those living with diabetes,” said Ben Williams, Ph.D., T1D Program Officer at the Helmsley Charitable Trust, “which is why we are excited to support this effort to develop an innovative therapy for people with the disease.”
In addition to providing funding for the project, TRxA’s unique drug accelerator model provides its grantees with translational and regulatory science expertise to help drive success and mitigate risks inherent to early-stage research for development of new therapeutics. “We are delighted to be partnering with the Helmsley Charitable Trust on this transformative T1D project that addresses an area of high unmet medical need in the diabetes community,” shared TRxA Executive Director Maaike Everts, Ph.D. “This effort brings together some of the brightest minds in biology, chemistry and drug discovery, which is critical for successful translation of ideas into new drugs available for patients.”
This grant complements C-Path’s broader commitment to foster collaboration among scientists and stakeholders by expediting the development of safe and effective therapies through its T1D Consortium (T1DC), of which the Helmsley Charitable Trust is also a partner. Founded in 2017, T1DC is working to achieve regulatory endorsement of Clinical Trial Simulation Tools in both new-onset and prevention of T1D to improve clinical trial design, accelerate development of new therapies, and positively impact the entire T1D community.
To learn more about TRxA, click here or email us at TRxA@c-path.org. More information about C-Path’s T1DC is available here.
Notes:
Feroz R. Papa, M.D. Ph.D. is Professor of Medicine at the University of California, San Francisco (UCSF).
Bradley J. Backes, Ph.D. is Associate Professor of Medicine at UCSF
Dustin J. Maly, Ph.D. is a Professor of Chemistry at the University of Washington, Seattle.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
About The Leona M. and Harry B. Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $4.5 billion for a wide range of charitable purposes. The Helmsley Type 1 Diabetes (T1D) Program is the largest private foundation funder in the world with a focus on T1D, with more than $1 billion to date committed to transform the trajectory of the disease and to accelerate access to 21st century care, everywhere. For more information on Helmsley and its programs, visit helmsleytrust.org
About TRxA
Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) is a global drug accelerator focused on supporting academic scientists in advancing novel therapeutics from university-based labs to drug development pipelines of pharmaceutical companies and, ultimately, the clinic. As a nonprofit neutral convener of patient groups, academia, pharmaceutical companies and regulatory agencies, C-Path brings a breadth of scientific and drug development planning not available in other accelerator programs. TRxA is uniquely situated to leverage the expertise available through C-Path’s >20 disease-based consortia, as well as regulatory expertise and project management, to empower academic investigators to succeed in bringing safe and effective treatments to patients. For more information, visit c-path.org/trxa or email trxa@c-path.org.
Media Contacts:
Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org
Kissy Black
C-Path
615.310.1894
kblack@c-path.org
END
C-Path’s TRxA announces $1 million award for drug development project in type 1 diabetes
2024-11-19
ELSE PRESS RELEASES FROM THIS DATE:
Changing the definition of cerebral palsy
2024-11-19
In the United States, there are currently more adults living with cerebral palsy than children.
Despite this, the Centers for Disease Control and Prevention still label cerebral palsy as “the most common motor disability in childhood.”
This definition not only ignores cerebral palsy as a lifelong condition but contributes to a lopsided research focus directed only at pediatric care and not care into adulthood and across the lifespan, experts say.
University of Michigan Health’s Mark Peterson, Ph.D., M.S., FACSM, a professor of physical medicine and rehabilitation, has been working to make sure the definition of cerebral ...
New research could pave way for vaccine against deadly wildlife disease
2024-11-19
Images
When Sean Crosson was a child growing up in rural Texas, he learned about vaccinating cattle against Bang’s disease from his high school agriculture teacher. The disease’s name amused him at the time.
Now, Crosson, a Professor Rudolph Hugh Endowed Chair in Michigan State University’s Department of Microbiology, Genetics and Immunology, has been awarded a $2.4 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to study the cause of that very disease, Brucella abortus.
Brucella abortus causes brucellosis disease, which, in addition to being known as Bang’s disease is also referred ...
Listening for early signs of Alzheimer’s disease #ASA187
2024-11-19
MELVILLE, N.Y., Nov. 19, 2024 – Alzheimer’s disease affects more than 50 million people worldwide, often devastating both the individuals who have it and their families and loved ones. It has no known cure, and the slow, progressive nature of the disease makes early diagnosis difficult.
Researchers from École de Technologie Supérieure and Dartmouth University are investigating the use of earpiece microphones to spot early signs of Alzheimer’s. Miriam Boutros will present their work on Tuesday, Nov. 19, at 4:15 p.m. ET, as part of the virtual 187th Meeting of the Acoustical Society of America, running Nov. 18-22, 2024.
People with Alzheimer’s ...
Research Spotlight: Gastroenterology education improved through inpatient care teaching model
2024-11-19
How would you summarize your study for a lay audience?
Gastroenterologists who focus primarily on providing inpatient care, called GI Hospitalists, are becoming more common across the U.S. We developed a survey to assess the effect of GI Hospitalists on fellowship education and found that GI Hospitalists improve education through superior endoscopy teaching and longitudinal feedback.
What knowledge gap does your study help to fill?
The aim of this study was to directly assess GI fellows’ perceptions of the educational impact of GI Hospitalist faculty on GI fellowship training. ...
Texas A&M researchers uncover secrets of horse genetics for conservation, breeding
2024-11-19
Researchers at the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) are helping uncover new information about the Y chromosome in horses, which will help owners identify optimal lineages for breeding and help conservationists preserve breed diversity.
“Because of its complex structure, the Y chromosome is much harder to sequence, making our knowledge of it far from complete,” said Dr. Gus Cothran, a professor emeritus in the VMBS’ Department of Veterinary Integrative Biosciences (VIBS). “In fact, scientists used to believe that the Y chromosome ...
Bioeconomy in Colombia: The race to save Colombia's vital shellfish
2024-11-19
Along Colombia's Pacific coast, a small shellfish called piangua has been a crucial part of local communities for generations. This humble mollusk is a vital source of income and nutrition for many coastal residents. As a regional resource that can be sustainably utilized, it represents a bioeconomy opportunity and is an example for other regions. But now, scientists are raising the alarm about its future.
A new study reveals that piangua populations are showing concerning signs of decline, largely due to overharvesting. Researchers used cutting-edge DNA analysis to examine these shellfish in two key locations along Colombia's ...
NFL’s Colts bring CPR education to flag football to improve cardiac emergency outcomes
2024-11-19
INDIANAPOLIS, November 18, 2024— The American Heart Association and the Indianapolis Colts this past weekend brought cardiopulmonary resuscitation (CPR) and automated external defibrillator (AED) training to the Colts Regional Flag Football tournament. At the Kickoff event held at the Indiana Farm Bureau Football Center on Saturday, Nov. 16 more than 100 youth athletes, coaches and league administrators learned lifesaving skills to build their confidence and capabilities to respond in the event of a cardiac emergency. The following day, walk-up style Hands-Only CPR instruction was again available to guests attending the tournament at the Center Grove Bantom ...
Research: Fitness more important than fatness for a lower risk of premature death
2024-11-19
As rates of obesity, as defined by body mass index (BMI), continue to climb in the United States, so have efforts to lose weight, including a new era of weight-loss drugs. Yet a new systematic review and meta-analysis published today in the British Journal of Sports Medicine found that cardiorespiratory fitness was a stronger predictor of both cardiovascular disease and all-cause mortality than BMI.
The researchers found that fit individuals across all BMI categories had statistically similar risks of death from all causes or cardiovascular disease. By contrast, unfit individuals ...
Researchers use biophysics to design new vaccines against RSV and related respiratory viruses
2024-11-19
LA JOLLA, CA—In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can cause severe pneumonia and even death.
Vaccines against both viruses, however, have been difficult to design. Now, Scripps Research scientists have analyzed the structure and stability of a critical RSV and hMPV protein to better design vaccines that target it. Their research, ...
New study highlights physician perspectives on emerging anti-amyloid treatments for Alzheimer’s disease in Israel
2024-11-19
November 19, 2024 - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel – In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid treatments (ATT) for Alzheimer’s disease (AD), revealing a spectrum of opinions across key specialties. With Israel’s health system structured to provide universal healthcare, the high out-of-pocket costs for new AD therapies have raised questions among medical professionals about the feasibility and practicality of implementing these treatments.
The study, conducted ...